Summit Therapeutics SMMT Business Segments — Other operating income, net
Discontinued — last reported Q4 '24
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherOperatingIncomeExpenseNet.
The official record: Summit Therapeutics’s 10-K, filed February 24, 2025, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's business segments — other operating income, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's business segments — other operating income, net?
- Summit Therapeutics (SMMT) reported business segments — other operating income, net of $78.25K in Q4 2024.
- How has Summit Therapeutics's business segments — other operating income, net changed year-over-year?
- Summit Therapeutics's business segments — other operating income, net decreased by 68.7% year-over-year, from $250.25K to $78.25K.
- What is the long-term trend for Summit Therapeutics's business segments — other operating income, net?
- Over 2 years (2022 to 2024), Summit Therapeutics's business segments — other operating income, net has grown at a -85.3% compound annual growth rate (CAGR), from $14.42M to $313K.
- What does business segments — other operating income, net mean?
- The net total of miscellaneous income and expenses generated by the segment from non-core business activities.
- How do you interpret business segments — other operating income, net?
- An increase indicates higher secondary income or lower incidental costs, while a decrease suggests reduced non-core gains or higher incidental expenses.
- How does business segments — other operating income, net compare across companies?
- Similar to 'Other Operating Income' or 'Miscellaneous Income' found in the segment reporting of other biopharmaceutical firms, often reflecting R&D grants or collaborative reimbursements.